Back to top
more

Agenus (AGEN)

(Real Time Quote from BATS)

$12.28 USD

12.28
394,950

+1.16 (10.43%)

Updated May 22, 2024 02:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Agenus (AGEN) Upgraded to Buy: Here's Why

by Zacks Equity Research

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of 11.43% and 22.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Agenus (AGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agenus' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Agenus.

Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

Why Agenus (AGEN) Stock Might be a Great Pick

by Zacks Equity Research

Agenus (AGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Agenus (AGEN) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Agenus (AGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Agenus (AGEN) betters loss estimates and also beats on sales in the fourth quarter. The company gets a Fast Track tag for balstilimab & zalifrelimab combo to address the second-line cervical cancer.

Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of 46.34% and 102.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Agenus (AGEN) Q4 Earnings Expected to Decline

by Zacks Equity Research

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Immunomedics (IMMU) Reports Wider-Than-Expected Q4 Loss

by Zacks Equity Research

Immunomedics (IMMU) posts wider-than-expected Q4 loss. Its BLA seeking accelerated approval for sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) is accepted for filing by FDA.

ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales

by Zacks Equity Research

ACADIA (ACAD) beats on earnings and revenues in the fourth quarter.

Gilead Sciences (GILD) Surges: Stock Moves 6.6% Higher

by Zacks Equity Research

Gilead Sciences (GILD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Global Blood (GBT) Q4 Earnings Miss, Voxelotor Gets FDA Nod

by Zacks Equity Research

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2019. The FDA approves voxelotor (Oxbryta) for the treatment of SCD in adults, and children 12 years of age and older.

Horizon Therapeutics' (HZNP) Q4 Earnings Beat Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) beat earnings and sales estimates in the fourth quarter of 2019.

Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

by Zacks Equity Research

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease

by Zacks Equity Research

Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.

Innate Pharma's Filing for Leukemia Drug Accepted in Europe

by Zacks Equity Research

The EMA accepts Innate's (IPHA) marketing application for Lumoxiti, developed to treat relapsed/refractory hairy cell leukemia in adult patients having received minimum two prior systemic therapies.

Pulmatrix Surges on License Agreement With Johnson & Johnson

by Zacks Equity Research

Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.

Amicus Progresses on Pipeline Development Amid Competition

by Zacks Equity Research

Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.

Arena (ARNA) Expands Strategic Deal With Beacon Discovery

by Zacks Equity Research

Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.

All You Need to Know About Agenus (AGEN) Rating Upgrade to Buy

by Zacks Equity Research

Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agenus (AGEN) Up 24.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

Moving Average Crossover Alert: Agenus

by Zacks Equity Research

Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.